Sun Pharma Advanced Research Company Ltd. (SPARC) has announced the successful completion of patient enrollment for the PROSEEK study, a significant global Phase 2 clinical trial focusing on early Parkinson’s disease. This large-scale study has successfully enrolled 506 patients across 84 sites in the United States, Europe, and India, positioning it among the most extensive […]
Sun Pharmaceutical Industries has secured approval for SEZABY (phenobarbital sodium powder for injection) from the US Food and Drug Administration (FDA) for the treatment of neonatal seizures. According to Sun Pharmaceutical, the approval makes SEZABY the first and only product to be indicated specifically in the US for treating neonatal seizures in term and preterm […]
Sun Pharma Advanced Research Company (SPARC) has signed a licensing agreement with Visiox Pharma to award exclusive worldwide rights (except for India and Greater China) for developing and commercializing its ophthalmic drug candidates — PDP-716 and SDN-037. As per the terms of the licensing deal, Sun Pharma Advanced Research Company will be entitled to get […]
Sun Pharma Advanced Research Company (SPARC) has signed an agreement with US-based Biomodifying for the exclusive licensing of the latter’s intellectual property (IP), including all patents and patent applications owned or controlled by it in addition to antibodies developed for various uses including for cancer. The India-based clinical stage biopharma company, which is owned by […]
Sun Pharma Advanced Research Company (SPARC) has succeeded in a phase 3 clinical trial for PDP-716 ophthalmic suspension, its investigational drug for the treatment of open angle glaucoma or ocular hypertension. The late-stage clinical trial met its pre-specified primary endpoint by showing that daily once dosing of PDP-716 is equivalent to Alphagan P 0.1% dosed […]